No Data
No Data
Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Cuts Target Price to $195
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development
BMO Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
Sarepta Therapeutics: A Promising Investment With Strategic Market Position and Innovative ARO-DM1 Program
RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Cuts Target Price to $165
RBC Cuts Price Target on Sarepta Therapeutics to $165 From $182, Keeps Outperform Rating
Unlock the Full List